What Is GLP-3? Next Generation Weight Loss Drugs Explained
An evidence-based explainer on GLP-3, how it differs from GLP-1, what next-generation weight loss drugs are in development, and what patients should realistically expect.
The GLP-3 label: what it actually means
If you have seen the term 'GLP-3' in headlines or social media, it is important to understand that this is not an official pharmacological classification. There is no FDA-approved drug category called GLP-3. The term has emerged as informal shorthand — sometimes used by journalists, influencers, and marketers — to describe the next wave of weight loss drugs that target multiple hormonal pathways beyond what current GLP-1 receptor agonists do.
The scientific reality is more nuanced. Current GLP-1 drugs like semaglutide target a single receptor (GLP-1R). Tirzepatide, already approved, targets two receptors (GLP-1 and GIP). The drugs in development that get called 'GLP-3' are typically triple agonists that target three receptor pathways: GLP-1, GIP, and glucagon. The glucagon receptor is the new element — it may enhance energy expenditure and fat metabolism beyond what dual agonists achieve.
ClearlyMeds is independently researched. Revenue never influences our rankings, and every guide is written to help readers understand tradeoffs in plain English rather than push a single provider.
- GLP-3 is not an official drug class or FDA designation
- It typically refers to triple receptor agonists (GLP-1 + GIP + glucagon)
- Several candidates are in late-stage clinical trials but none are approved yet
How multi-receptor agonists work
Single-target GLP-1 drugs primarily reduce appetite and slow gastric emptying. They work, but the body is complex, and targeting only one pathway leaves other metabolic levers untouched. The theory behind multi-receptor agonists is that activating additional pathways can produce additive or synergistic effects on weight loss, glucose control, and metabolic health.
GIP receptor activation, as seen in tirzepatide, appears to enhance insulin sensitivity and may work synergistically with GLP-1 signaling. Adding glucagon receptor activation — the distinguishing feature of triple agonists — could increase energy expenditure by promoting fat oxidation and thermogenesis. In simpler terms, while GLP-1 drugs mainly make you eat less, triple agonists may also make your body burn more energy at rest.
The clinical data so far is promising but preliminary. Retatrutide, Eli Lilly's triple agonist, showed up to 24% body weight loss in Phase 2 trials — more than any approved weight loss drug. But Phase 2 results do not always replicate in larger Phase 3 trials, and safety profiles take years to fully characterize.
Key drugs in development
Retatrutide (Eli Lilly) is the most discussed triple agonist. Phase 2 data published in 2023 showed mean weight loss of up to 24.2% at 48 weeks. Phase 3 trials are underway with results expected in 2026-2027. If approved, it would be the first true triple agonist on the market. The main questions are long-term safety, side effect management at higher doses, and how pricing will compare to tirzepatide.
Survodutide (Boehringer Ingelheim) is a dual GLP-1/glucagon agonist — not a triple agonist, but still a step beyond current GLP-1 drugs. Phase 2 data showed approximately 19% weight loss at 46 weeks. It is also being studied for metabolic dysfunction-associated steatohepatitis (MASH), formerly known as NASH. Phase 3 results are expected in late 2026.
CagriSema (Novo Nordisk) combines semaglutide with cagrilintide, an amylin receptor agonist. This is a different approach — rather than a single molecule hitting multiple receptors, it pairs two separate drugs. Phase 3 data showed approximately 22.7% weight loss. Novo Nordisk has filed for regulatory review, and approval could come in late 2026 or 2027.
Pemvidutide (Altimmune) is another dual GLP-1/glucagon agonist in earlier-stage development. Phase 2 data showed approximately 15.6% weight loss at 48 weeks. It is also being evaluated for liver fat reduction.
What patients should realistically expect
The hype around next-generation weight loss drugs is understandable — the Phase 2 numbers are genuinely impressive. But patients should calibrate expectations carefully. Drug development timelines are long, and the gap between promising trial data and real-world availability can be years. Regulatory review, manufacturing scale-up, insurance coverage negotiations, and supply chain logistics all create delays.
Even when these drugs become available, they will not be a magic solution. Multi-receptor agonists may produce more weight loss, but they are also likely to have more complex side effect profiles. Targeting the glucagon receptor, for example, could affect liver function, lipid metabolism, and blood sugar in ways that require closer monitoring than current GLP-1 drugs.
The practical advice for patients in April 2026 is this: do not delay effective treatment while waiting for a hypothetical future drug. Current GLP-1 medications work well for many patients. If you are a candidate now, starting treatment now is a reasonable decision. When next-generation drugs become available, switching or adjusting will be a conversation to have with your clinician based on your actual response and needs.
This guide is educational and not a substitute for personal medical advice. Eligibility, contraindications, and monitoring needs differ across individuals, which is why treatment decisions should be reviewed with a licensed clinician.
How this affects provider comparisons today
The emergence of next-generation drugs has implications for how patients should evaluate telehealth providers. Platforms that demonstrate clinical flexibility — the ability to adjust treatment plans as new medications become available — will be better positioned to serve patients long-term. A provider locked into a single compounding pathway may struggle to integrate new branded drugs when they launch.
Providers like Ro, FORM Health, and MEDVi that offer multiple medication pathways, insurance support, and structured clinical oversight are more likely to incorporate next-gen drugs smoothly. Purely compounding-focused providers may face disruption if their business model depends on a medication landscape that is rapidly changing.
The bottom line: choose a provider based on current needs, but give weight to clinical flexibility and medication access breadth. The weight loss medication market is evolving fast, and your provider should be able to evolve with it.